ASH 2025: Rigel's CEO Raul Rodriguez discusses the company's IRAK1/4 data in patients with lower-risk MDS
- Dec 7, 2025
- 1 min read
Updated: Dec 9, 2025
He describes how Rigel became focused on both IRAK 1 and 4, a novel mechanism in the area of hematology, and what is next for the company after the ASH presentation.
Coverage brought to you by










.png)
